MENU
PFE
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

Pfizer (PFE) Earnings Date & Reports

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion... Show more

A.I. Advisor
published Earnings

PFE is expected to report earnings to fall 18.84% to 70 cents per share on February 02

Pfizer PFE Stock Earnings Reports
Q4'26
Est.
$0.71
Q3'26
Beat
by $0.15
Q2'26
Beat
by $0.09
Q1'26
Beat
by $0.03
Q4'25
Beat
by $0.08
The last earnings report on November 03 showed earnings per share of 87 cents, beating the estimate of 72 cents. With 8.16M shares outstanding, the current market capitalization sits at 167.51B.
A.I.Advisor
Nov 03, 2026

Pfizer (PFE) Third-Quarter 2026 Earnings Recap: New Drugs Offset COVID's Fade

Key Takeaways

  • Pfizer reported third-quarter 2026 revenue of $16.58 billion, roughly flat year over year but ahead of analyst consensus estimates.
  • Reported diluted EPS (earnings per share) came in at $0.56, while adjusted diluted EPS was $0.87, topping Wall Street expectations.
  • Non-COVID products grew 7% operationally, and launched and acquired products surged 32%, offsetting steep declines in Comirnaty and Paxlovid.
  • Management raised full-year 2026 revenue guidance to $62.0–$64.0 billion and narrowed adjusted EPS guidance to $2.95–$3.05.
  • Pfizer appointed Cecile Guegan as Chief Financial Officer, effective November 1, 2026.
  • For more on Pfizer's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated PFE pages.
  • Discover actionable market ideas with Trending AI Robots.

Earnings Context and Why It Matters

Pfizer remains in the midst of a well-documented portfolio transition. As pandemic-era sales of its COVID-19 vaccine Comirnaty and oral treatment Paxlovid continue to normalize downward, investors are closely watching whether newer and acquired medicines can fill the gap fast enough to support durable growth. The third-quarter report was therefore an important test of Pfizer's commercial execution and its cost-realignment program. Strong momentum from franchises such as Eliquis, Padcev, the Vyndaqel family, Nurtec, and Lorbrena has become central to the investment case, while the company's obesity and oncology pipeline adds a longer-term catalyst. A guidance raise signaled management's confidence despite lingering patent-expiration (loss of exclusivity, or LOE) pressures.

Reported Results

For the third quarter of 2026, Pfizer reported revenue of $16.58 billion, essentially flat on both a reported and operational basis compared with $16.65 billion a year earlier. The result came in ahead of consensus estimates of roughly $16.1 billion. Reported diluted EPS was $0.56, down from $0.62 a year ago, while adjusted diluted EPS held steady at $0.87, above the analyst consensus of approximately $0.72 to $0.73.

Growth was driven by the non-COVID portfolio, which rose 7% operationally, and by launched and acquired products, which grew 32% operationally. Eliquis increased 25%, Padcev rose 55%, the Vyndaqel family climbed 12%, Nurtec ODT/Vydura advanced 33%, and Lorbrena gained 43% operationally. These gains were offset by Paxlovid, down 63%, Comirnaty, down 29%, and the Prevnar family, down 10%. Adjusted R&D (research and development) spending rose 18% operationally, reflecting investment in oncology and obesity programs.

Pfizer raised full-year 2026 revenue guidance by $1.5 billion at the midpoint to $62.0–$64.0 billion and narrowed adjusted diluted EPS guidance to $2.95–$3.05, up from $2.80–$3.00 previously.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring names like Pfizer (PFE) ahead of and after earnings events, it offers a streamlined way to surface relevant opportunities.

Market Reaction and Investor Sentiment

Reaction to the report was muted despite the headline beats. Pfizer shares moved only modestly around the release, with early trading showing a slight decline of roughly 1% in some sessions even as pre-market indications initially ticked higher. The restrained response reflects investor focus on the still-flat overall revenue picture and the ongoing drag from COVID-19 products and the Prevnar franchise, rather than the adjusted EPS outperformance. The raised guidance and 32% growth in launched and acquired products were viewed as encouraging, but markets continue to weigh near-term LOE headwinds and the pace of the portfolio's transition toward sustainable growth.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should track several catalysts that will shape Pfizer's trajectory. First, the commercialization of the obesity portfolio remains a key swing factor. Management plans to advance roughly 10 active and planned Phase 3 trials in 2026, including studies for the investigational monthly GLP-1 (glucagon-like peptide-1) peptide berobenatide, with potential first approvals targeted for 2028.

Second, oncology execution will matter. The legacy Seagen portfolio grew 39% year over year in the U.S., and further uptake of Padcev, along with late-stage readouts such as Elrexfio in multiple myeloma and the next-generation CDK4 inhibitor atirmociclib, could reinforce the growth narrative.

Third, cost discipline and margin trends warrant attention. Pfizer remains on track to deliver nearly all of its targeted $7.2 billion in net savings by the end of 2026, with an additional $2.5 billion expected from 2027 through 2029. Finally, investors should monitor the impact of upcoming patent expirations (LOEs), COVID-19 product guidance of approximately $4 billion for the full year, and how the newly appointed CFO approaches capital allocation, dividends, and potential share repurchases.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations